PYC Therapeutics Ltd (PYC) - Total Assets
Based on the latest financial reports, PYC Therapeutics Ltd (PYC) holds total assets worth AU$183.28 Million AUD (≈ $129.68 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See PYC book value for net asset value and shareholders' equity analysis.
PYC Therapeutics Ltd - Total Assets Trend (2004–2025)
This chart illustrates how PYC Therapeutics Ltd's total assets have evolved over time, based on quarterly financial data.
PYC Therapeutics Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
PYC Therapeutics Ltd's total assets of AU$183.28 Million consist of 96.9% current assets and 3.1% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$153.05 Million | 83.5% |
| Accounts Receivable | AU$24.07 Million | 13.1% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$1.90 Million | 1.0% |
| Intangible Assets | AU$3.85 Million | 2.1% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2004–2025)
This chart illustrates how PYC Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PYC Therapeutics Ltd (PYC) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PYC Therapeutics Ltd's current assets represent 96.9% of total assets in 2025, an increase from 0.0% in 2004.
- Cash Position: Cash and equivalents constituted 83.5% of total assets in 2025, up from 67.4% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 28.0% in 2004.
- Asset Diversification: The largest asset category is cash and equivalents at 83.5% of total assets.
PYC Therapeutics Ltd Competitors by Total Assets
Key competitors of PYC Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
PYC Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.41 | 9.40 | 36.23 |
| Quick Ratio | 14.41 | 11.38 | 36.23 |
| Cash Ratio | 12.43 | 7.34 | 10.26 |
| Working Capital | AU$165.21 Million | AU$76.51 Million | AU$24.86 Million |
PYC Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between PYC Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.27 |
| Latest Market Cap to Assets Ratio | 2.82 |
| Asset Growth Rate (YoY) | 100.9% |
| Total Assets | AU$183.28 Million |
| Market Capitalization | $517.68 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values PYC Therapeutics Ltd's assets at a significant premium (2.82x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: PYC Therapeutics Ltd's assets grew by 100.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for PYC Therapeutics Ltd (2004–2025)
The table below shows the annual total assets of PYC Therapeutics Ltd from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$183.28 Million ≈ $129.68 Million |
+100.88% |
| 2024-06-30 | AU$91.24 Million ≈ $64.56 Million |
+145.49% |
| 2023-06-30 | AU$37.17 Million ≈ $26.30 Million |
-18.05% |
| 2022-06-30 | AU$45.35 Million ≈ $32.09 Million |
-21.73% |
| 2021-06-30 | AU$57.94 Million ≈ $41.00 Million |
+83.67% |
| 2020-06-30 | AU$31.55 Million ≈ $22.32 Million |
+370.75% |
| 2019-06-30 | AU$6.70 Million ≈ $4.74 Million |
+96.00% |
| 2018-06-30 | AU$3.42 Million ≈ $2.42 Million |
-66.96% |
| 2017-06-30 | AU$10.35 Million ≈ $7.32 Million |
+42.42% |
| 2016-06-30 | AU$7.27 Million ≈ $5.14 Million |
+306.85% |
| 2015-06-30 | AU$1.79 Million ≈ $1.26 Million |
-60.53% |
| 2014-06-30 | AU$4.52 Million ≈ $3.20 Million |
+99.97% |
| 2013-06-30 | AU$2.26 Million ≈ $1.60 Million |
-35.27% |
| 2012-06-30 | AU$3.50 Million ≈ $2.47 Million |
-38.26% |
| 2011-06-30 | AU$5.66 Million ≈ $4.01 Million |
+260.57% |
| 2010-06-30 | AU$1.57 Million ≈ $1.11 Million |
-54.98% |
| 2009-06-30 | AU$3.49 Million ≈ $2.47 Million |
-0.90% |
| 2008-06-30 | AU$3.52 Million ≈ $2.49 Million |
-0.42% |
| 2007-06-30 | AU$3.53 Million ≈ $2.50 Million |
+24.78% |
| 2006-06-30 | AU$2.83 Million ≈ $2.00 Million |
-53.45% |
| 2005-06-30 | AU$6.08 Million ≈ $4.31 Million |
+418.27% |
| 2004-06-30 | AU$1.17 Million ≈ $830.68K |
-- |
About PYC Therapeutics Ltd
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atroph… Read more